As the government shutdown drags in to its second month, physicians who treat opioid use disorders are being backed against a wall.
For the first time in history, Americans’ risk for dying from an opioid overdose is higher than their risk for dying in a car accident.
Sandoz and Pear Therapeutics announced the launch of reSET-O, a new digital therapeutic for patients aged ≥18 years with opioid use disorder (OUD) currently under clinician care.
The Protecting Canadians from Unsafe Drugs Act passed into law in 2014 empowered the minister of health to recall a drug if they “believe that a therapeutic product presents a serious or imminent risk of injury to health.”
More than two-thirds of drug overdose deaths in 2017 involved an opioid, with increases in overdose deaths from all opioids and synthetic opioids seen from 2016 to 2017.
reSET-O is intended for use as an adjunct to outpatient treatment that includes transmucosal buprenorphine (medication-assisted-treatment [MAT]) and contingency management for patients aged ≥18 years who are currently under clinician supervision.
Clinicians who are highly concerned about opioid misuse, addiction, and psychological dependence may be more confident but also more reluctant to prescribe opioids.
Patients with opioid use disorders who required hospitalization with lengthy antibiotic therapy had better outcomes with addiction medicine consultation.
In an effort to address the ongoing opioid crisis adequately, a set of measures complementing the current efforts at state and federal levels would need to be implemented for a more “coordinated and comprehensive approach” to the issue.